Skip to main content
AAPL-0.36%MSFT+0.70%NVDA+3.73%GOOGL-1.24%AMZN+0.68%TSM-3.68%SPCX+3.16%AVGO+2.46%META+0.62%TSLA+0.87%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+3.96%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.99%0700.HK-3.69%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.84%UNH-5.42%ORCL-3.38%3988.HK-0.63%BAC-1.28%HD-2.45%GE+0.38%0857.HK-0.38%1816.HK-2.30%1288.HK-0.86%0005.HK-1.42%PM-0.85%NVS-0.67%HSBA.L-1.95%MS-1.10%INTC-0.54%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.68%NZDJPY-0.65%AUDUSD-0.57%NZDUSD-0.51%GBPAUD+0.49%GBPNZD+0.46%EURJPY-0.44%GBPTRY+0.41%CHFJPY-0.39%CADJPY-0.36%AUDCAD-0.33%GBPHKD+0.32%EURUSD-0.31%AUDCHF-0.30%NZDCAD-0.30%USDCHF+0.29%GBPMXN-0.28%EURAUD+0.26%NZDCHF-0.25%EURGBP-0.24%GBPCHF+0.24%USDCAD+0.23%EURNZD+0.21%GBPJPY-0.19%USDTHB-0.18%GBPCAD+0.16%USDTRY+0.16%USDILS+0.16%USDJPY-0.14%USDCNH-0.10%USDDKK+0.10%EURCNH-0.08%EURSGD-0.07%NZDMXN+0.07%EURCAD-0.07%NZDSGD+0.07%CHFSGD-0.06%GBPUSD-0.05%AUDNOK+0.05%SGDJPY+0.05%AUDNZD-0.05%CADCHF+0.05%USDCOP-0.04%USDMXN+0.03%USDSGD+0.02%AUDSGD+0.01%EURCHF-0.01%USDHKD+0.01%GBPSGD-0.01%USDZAR0.00%USDNOK0.00%PLNJPY0.00%GBPZAR0.00%USDSEK0.00%USDPLN0.00%NOKJPY0.00%EURHKD0.00%EURPLN0.00%EURCZK0.00%EURSEK0.00%EURZAR0.00%EURNOK0.00%AUDDKK0.00%CHFSEK0.00%CHFNOK0.00%EURDKK0.00%XAUUSD-0.47%GAUUSD-0.46%XNGUSD+0.46%XPTUSD-0.39%GAGUSD-0.36%XAGUSD-0.36%HG1-0.11%USOIL-0.08%COTTON0.00%COFFEE0.00%COCOA0.00%W10.00%BTCUSD-0.19%ETHUSD+58.05%USDTUSD-0.01%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+0.95%ZECUSDT+6.50%XMRUSDT+3.02%DOGEUSD+59.04%LINKUSD+1.44%XLMUSD+2.65%BCHUSDT+1.44%LTCUSD+50.36%UNIUSD+2.27%TONUSD+63.46%SUIUSD+2.10%HBARUSDT+1.13%TAOUSDT+3.44%AAVEUSD+3.57%ONDOUSDT+0.85%ICPUSDT-8.30%DOTUSDT+1.18%WLDUSDT+2.24%ARBUSDT+0.63%INJUSDT+7.34%ATOMUSDT-0.39%STXUSDT+5.51%PYTHUSDT+2.05%TIAUSDT+0.91%FETUSDT+0.61%SEIUSDT+1.04%JUPUSDT+8.18%GRTUSDT+4.71%OPUSDT-2.36%IOTAUSDT+3.17%POLUSDT+4.01%WIFUSDT+1.17%AXSUSDT+1.56%EOSUSDT+2.67%FARTCOINUSDT-1.22%IMXUSDT+2.00%GALAUSDT-1.23%DYDXUSDT+2.29%ORDIUSDT+0.10%NOTUSDT+1.77%RONINUSDT+2.00%AAPL-0.36%MSFT+0.70%NVDA+3.73%GOOGL-1.24%AMZN+0.68%TSM-3.68%SPCX+3.16%AVGO+2.46%META+0.62%TSLA+0.87%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+3.96%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.99%0700.HK-3.69%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.84%UNH-5.42%ORCL-3.38%3988.HK-0.63%BAC-1.28%HD-2.45%GE+0.38%0857.HK-0.38%1816.HK-2.30%1288.HK-0.86%0005.HK-1.42%PM-0.85%NVS-0.67%HSBA.L-1.95%MS-1.10%INTC-0.54%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.68%NZDJPY-0.65%AUDUSD-0.57%NZDUSD-0.51%GBPAUD+0.49%GBPNZD+0.46%EURJPY-0.44%GBPTRY+0.41%CHFJPY-0.39%CADJPY-0.36%AUDCAD-0.33%GBPHKD+0.32%EURUSD-0.31%AUDCHF-0.30%NZDCAD-0.30%USDCHF+0.29%GBPMXN-0.28%EURAUD+0.26%NZDCHF-0.25%EURGBP-0.24%GBPCHF+0.24%USDCAD+0.23%EURNZD+0.21%GBPJPY-0.19%USDTHB-0.18%GBPCAD+0.16%USDTRY+0.16%USDILS+0.16%USDJPY-0.14%USDCNH-0.10%USDDKK+0.10%EURCNH-0.08%EURSGD-0.07%NZDMXN+0.07%EURCAD-0.07%NZDSGD+0.07%CHFSGD-0.06%GBPUSD-0.05%AUDNOK+0.05%SGDJPY+0.05%AUDNZD-0.05%CADCHF+0.05%USDCOP-0.04%USDMXN+0.03%USDSGD+0.02%AUDSGD+0.01%EURCHF-0.01%USDHKD+0.01%GBPSGD-0.01%USDZAR0.00%USDNOK0.00%PLNJPY0.00%GBPZAR0.00%USDSEK0.00%USDPLN0.00%NOKJPY0.00%EURHKD0.00%EURPLN0.00%EURCZK0.00%EURSEK0.00%EURZAR0.00%EURNOK0.00%AUDDKK0.00%CHFSEK0.00%CHFNOK0.00%EURDKK0.00%XAUUSD-0.47%GAUUSD-0.46%XNGUSD+0.46%XPTUSD-0.39%GAGUSD-0.36%XAGUSD-0.36%HG1-0.11%USOIL-0.08%COTTON0.00%COFFEE0.00%COCOA0.00%W10.00%BTCUSD-0.19%ETHUSD+58.05%USDTUSD-0.01%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+0.95%ZECUSDT+6.50%XMRUSDT+3.02%DOGEUSD+59.04%LINKUSD+1.44%XLMUSD+2.65%BCHUSDT+1.44%LTCUSD+50.36%UNIUSD+2.27%TONUSD+63.46%SUIUSD+2.10%HBARUSDT+1.13%TAOUSDT+3.44%AAVEUSD+3.57%ONDOUSDT+0.85%ICPUSDT-8.30%DOTUSDT+1.18%WLDUSDT+2.24%ARBUSDT+0.63%INJUSDT+7.34%ATOMUSDT-0.39%STXUSDT+5.51%PYTHUSDT+2.05%TIAUSDT+0.91%FETUSDT+0.61%SEIUSDT+1.04%JUPUSDT+8.18%GRTUSDT+4.71%OPUSDT-2.36%IOTAUSDT+3.17%POLUSDT+4.01%WIFUSDT+1.17%AXSUSDT+1.56%EOSUSDT+2.67%FARTCOINUSDT-1.22%IMXUSDT+2.00%GALAUSDT-1.23%DYDXUSDT+2.29%ORDIUSDT+0.10%NOTUSDT+1.77%RONINUSDT+2.00%

J&J backs cancer device and $100m depression bet

NEWS

November 12, 2026 at 18:07 UTC

4 min read
Unbranded medical treatment console in a hospital room as JNJ backs new prostate cancer technology JNJ

Key Points

  • 01Johnson & Johnson (JNJ) has led a new funding round in Francis Medical for a prostate cancer device.
  • 02Francis aims to use the capital to seek premarket approval for its Vanquish water‑vapor therapy system.
  • 03J&J (JNJ)’s venture arm co‑led Delix Therapeutics’ $100 million Series C financing.
  • 04Delix will fund Phase II work on zalsupindole for recurrent major depressive disorder.

J&J boosts cancer device and depression therapeutics

Johnson & Johnson is expanding its presence in both oncology devices and mental health drugs by backing two specialized healthcare companies. It has led a funding round in Francis Medical for a minimally invasive prostate cancer device, while its Johnson & Johnson Innovation – JJDC venture arm has co‑led a $100 million Series C financing in Delix Therapeutics to advance a psychedelic‑inspired depression treatment.

Francis Medical financing for prostate cancer device

Johnson & Johnson has led a funding round in Francis Medical, which develops minimally invasive therapies for urological cancers. Francis plans to use the capital to take its Vanquish water‑vapor therapy device through a premarket approval submission for the management of clinically localized prostate cancer. The company also intends to scale its commercial infrastructure, expand market‑access initiatives, and strengthen physician training and education programs.

The Vanquish system delivers thermal energy via water vapor to ablate prostate tissue while aiming to minimize impact on surrounding structures associated with urinary and sexual function. The device incorporates a deployable, variable‑distance needle and real‑time ultrasound monitoring to support precise targeting. This approach extends techniques already used for benign prostatic hyperplasia to the treatment of prostate cancer.

Physicians are already using Vanquish in commercial practice. The Food and Drug Administration granted 510(k) clearance for the system for prostate tissue ablation in December, and the first commercial procedure was performed in February. Francis brought the device to market with proceeds from an $80 million Series C financing completed last year, and the new funding is intended to support regulatory steps specific to prostate cancer.

The FDA has not yet assessed Vanquish for the treatment of any disease, including prostate cancer, and Francis’ planned premarket approval submission is expected to support use in this setting. The company is running a clinical trial in 235 people with intermediate‑risk, localized prostate cancer in the United States, and is monitoring patients for five years to build the evidence base for the technology.

Clinical data underpinning the Vanquish program

Francis published outcomes from its Vanquish clinical study. In June, Francis published outcomes for the first 110 patients enrolled in the trial.

J&J co‑leads $100 million Delix Therapeutics round

Alongside its device investment, Johnson & Johnson is also deepening its exposure to psychiatric therapeutics. Delix Therapeutics has raised $100 million in a Series C financing that closed on November 9, co‑led by Johnson & Johnson Innovation – JJDC and SV Health Investors’ Dementia Discovery Fund. Existing and new institutional investors also participated in the round.

The proceeds will fund development of Delix’s lead depression drug zalsupindole through Phase IIb proof‑of‑concept testing in recurrent major depressive disorder and support other candidates in the company’s neuroplastogen pipeline. Delix plans to start a placebo‑controlled Phase II trial of zalsupindole in the first half of 2027. The study is expected to enroll 240 patients who will be dosed either daily or two times a week for one month, with results expected in the first half of 2028.

Profile of zalsupindole and early clinical results

Zalsupindole is an oral compound inspired by 5‑MeO‑DMT and is designed to promote neuroplasticity without hallucinations. In a Phase Ib trial involving 18 adults with recurrent major depressive disorder, patients experienced a mean reduction of about 50% in depression scores one week after treatment. The improvement was maintained through day 36, four weeks after the final dose, in this early‑stage study.

Delix’s chief executive said the new capital enables the company to take zalsupindole through Phase II proof of concept. As part of the financing, a partner at SV Health Investors and a representative from Johnson & Johnson’s venture arm have joined Delix’s board. Prior to this Series C, Delix had raised $115 million across earlier financings.

Key Takeaways

  • 01Johnson & Johnson (JNJ) is using its venture arm to support both device and drug platforms in oncology and mental health.
  • 02Francis Medical’s Vanquish device has early commercial use and encouraging mid‑term biopsy and function data but still needs disease‑specific FDA approval.
  • 03The $100 million Delix financing positions zalsupindole for a larger, placebo‑controlled Phase II program after promising but small Phase Ib results.

J&J backs cancer device and $100m depression bet | Trading Dashboard